Plasma exchange is beneficial for patients with fulminant Wilson's disease

Article Abstract:

Therapeutic plasma exchange can efficiently remove excess copper from the blood of people suffering from Wilson's disease, while reducing their toxic serum copper levels. Characterized by the presence of too much copper in organs and tissues, Wilson's disease is a genetic autosomal recessive disorder whose complications include renal insufficiency and hemolytic anemia. The condition necessitates immediate hepatic transplantation, which is facilitated by the use of fresh-frozen plasma replacement.

Health aspects, Drug therapy, Transplantation of organs, tissues, etc., Organ transplantation, Tissue transplantation, Transplantation, Plasma exchange (Therapeutics), Wilson's disease

---

Very low infectivity detected in plasma

Article Abstract:

Results of a study conducted by Paul Brown and his colleagues at the National Institutes of Health indicated that human plasma protein concentrations support a minimal risk of getting Creutzfeldt-Jakob disease. The researchers also studied the distribution of infectivity among various components and plasma fractions associated with normal human blood. Their findings also showed that most of the infectivity in spiked human blood was correlated with cellular blood components.

Research, Creutzfeldt-Jakob disease, Blood proteins, Brown, Paul (American football coach)

---

Similar abstracts:

• Abstracts: Mortality over a period of 10 years in patients with peripheral arterial disease. Mortality after the treatment of hyperthyroidism with radioactive iodine
• Abstracts: All change for Millview. Patients' choice. The people's check-up
• Abstracts: Full range of lymphoid proliferations are possible after transplantation. Alphacypermethrin-treated bednets may be cost effective for malaria prevention
• Abstracts: No difference in GBV-C/HGV viremia in donors with normal or elevated ALT. Recombinant OspC used in an ELISA enables early diagnosis
• Abstracts: CDC sharpens tools for vaccine-safety surveillance. 2002 vaccine market: $7 billion. Unprecedented protection with prime/boost malaria vaccine

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.